by Shay Zakov | In this work, we review the reports provided by Pfizer to the FDA for the trial’s first interim analysis. The reports demonstrate severe flaws in the procedure of approving Pfizer’s Covid-19 vaccine based on data from the vaccine’s phase III clinical trial.
